Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadolinium Enhanced Dual-Energy CT for Pulmonary Embolism
NCT02163005Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gadoterate meglumine in pulmonary embolism (PE), sponsored by Massachusetts General Hospital. Planned start Dec 2016; status: withdrawn.
02
Drugs
gadoterate meglumine
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT02163005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163005.